In September, the telecommunications giant announced it was boosting its dividend by 1.25 cents a share to $0.69 per share, its 19th consecutive annual dividend increase. At the current share price, ...

Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex should be worth more than Pfizer by 2030.

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...

Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

The U.S. drugmaker submitted its sweetened bid, which matches Novo’s offer from Tuesday, valuing Metsera at $86.20 a share, ...

Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...